Table 2.

Combination therapy of targeted drugs and CAR-T

Type of molecular targeted	Antibody	CAR target antigen	Tumor	Findings	Reference
PD1	Pembrolizumab, cemiplimab	ROR1	NSCLC	Improved cytokine production and function of CAR-T cells	[177]
	Pembrolizumab	CD19	R/R-BCL	Decreased exhaustion markers	[179]
	Nivolumab	GD2	GBM	Enhanced tumor clearance	[178]
		L1CAM	Neuroblastoma	Enhanced targeted killing ability of CAR-T cells	[181]
PD-L1	Atezolizumab, avelumab	PSCA, CD19	PCa, lymphoma	Promoted transformation of M2 to M1 and reduced M2 abundance	[183]
BTK	Ibrutinib	CD19	BCL	Enhanced tumor clearance	[184]
PARP	Olaparib	EGFRvIII	BC	Reduced MDSC recruitment in tumor	[185]
		CD70	RCC	Increased infiltration of CD8+ CAR-T cells in the TME	[186]
AKT	MK-2206	EpCAM	CRC	Generated CAR-T cell populations with memory-like characteristics	[187]
	VIII	CD19	B-ALL	Reduced lactic acid production	[188]
TOPK	HI-TOPK-032	GPC3	HCC	Increased Tcm frequency	[189]

Abbreviations: B-ALL, B-cell acute lymphoblastic leukemia; BC, breast cancer; BCL, B-cell lymphoma; BTK, Bruton’s tyrosine kinase; CRC, colorectal cancer; EGFRvIII, epidermal growth factor receptor variant III; EpCAM, epithelial cell adhesion molecule; GBM, glioblastoma multiforme; GPC3, glypican-3; HCC, hepatocellular carcinoma; L1CAM, L1 cell adhesion molecule; PARP, poly ADP-ribose polymerase; PCa, prostate cancer; PSCA, prostate stem cell antigen; RCC, renal cell carcinoma; ROR1, tyrosine kinase-like orphan receptor 1; RR-BCL, relapsing or refractory B-cell lymphoma; Tcm, central memory T cell; TOPK, T-LAK cell-originated protein kinase; VIII, AKT inhibitor